ID: ALA4091817

Max Phase: Preclinical

Molecular Formula: C28H30N2

Molecular Weight: 394.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  c1ccc(-c2cccc(-n3cc(CNCC4CCCCC4)c4ccccc43)c2)cc1

Standard InChI:  InChI=1S/C28H30N2/c1-3-10-22(11-4-1)19-29-20-25-21-30(28-17-8-7-16-27(25)28)26-15-9-14-24(18-26)23-12-5-2-6-13-23/h2,5-9,12-18,21-22,29H,1,3-4,10-11,19-20H2

Standard InChI Key:  AEXWQRTZIUKQLU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 394.56

Molecular Weight (Monoisotopic): 394.2409

AlogP: 6.97

#Rotatable Bonds: 6

Polar Surface Area: 16.96

Molecular Species: BASE

HBA: 2

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 2

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 9.93

CX LogP: 7.27

CX LogD: 4.82

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.37

Np Likeness Score: -0.76

References

1. Yamada K, Levell J, Yoon T, Kohls D, Yowe D, Rigel DF, Imase H, Yuan J, Yasoshima K, DiPetrillo K, Monovich L, Xu L, Zhu M, Kato M, Jain M, Idamakanti N, Taslimi P, Kawanami T, Argikar UA, Kunjathoor V, Xie X, Yagi YI, Iwaki Y, Robinson Z, Park HM..  (2017)  Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.,  60  (16): [PMID:28771350] [10.1021/acs.jmedchem.7b00708]

Source

Source(1):

• Scientific Literature